CARDIOPROOF
Proof of Concept of Model-based Cardiovascular Prediction
| Coordinatore |
Organization address
address: LIVENZA 6 contact info |
| Nazionalità Coordinatore | Non specificata |
| Totale costo | 5˙891˙930 € |
| EC contributo | 4˙107˙000 € |
| Programma | FP7-ICT
Specific Programme "Cooperation": Information and communication technologies |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-10-01 - 2016-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
LYNKEUS
Organization address
address: LIVENZA 6 contact info |
IT (ROME) | coordinator | 0.00 |
| 2 |
DEUTSCHES HERZZENTRUM BERLIN
Organization address
address: Augustenburger Platz contact info |
DE (BERLIN) | participant | 0.00 |
| 3 |
ESI GROUP S.A.
Organization address
address: Avenue de Suffren contact info |
FR (PARIS) | participant | 0.00 |
| 4 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse contact info |
DE (MUNCHEN) | participant | 0.00 |
| 5 |
LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE
Organization address
address: Houghton Street contact info |
UK (LONDON) | participant | 0.00 |
| 6 |
MAAT FRANCE SARL
Organization address
address: IMPASSE DES PRES D EN BAS contact info |
FR (ARGONAY) | participant | 0.00 |
| 7 |
MEDIZINISCHE UNIVERSITAT GRAZ
Organization address
address: AUENBRUGGERPLATZ contact info |
AT (GRAZ) | participant | 0.00 |
| 8 |
OSPEDALE PEDIATRICO BAMBINO GESU
Organization address
address: PIAZZA SAN ONOFRIO contact info |
IT (ROMA) | participant | 0.00 |
| 9 |
SIEMENS AKTIENGESELLSCHAFT
Organization address
address: Wittelsbacherplatz contact info |
DE (MUENCHEN) | participant | 0.00 |
| 10 |
UNIVERSITY COLLEGE LONDON
Organization address
address: Gower Street contact info |
UK (LONDON) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
CARDIOPROOF is a proof-of-concept project that consolidates the outcomes of previous VPH projects and checks the applicability and effectiveness of available predictive modelling and simulation tools, validating them in interrelated clinical trials conducted in three European centres of excellence in cardiac treatment (from Germany, Italy and the UK). CARDIOPROOF focuses on patients with aortic valve disease and aortic coarctation, which, if left untreated, can ensue irreversible heart failure. As a result treatment becomes mandatory, but optimum timing and the best type of treatment still remain difficult to determine. With more than 50.000 interventions per year within the EU, the diseases addressed by CARDIOPROOF have a significant socio-economic impact. Present clinical guidelines are highly complex and rely mostly on imaging diagnostics and clinical parameters, without benefiting, as yet, from patient-specific disease modelling based prediction. CARDIOPROOF goes beyond the current state of the art by conducting validation trials aimed at covering and comparing the complete spectrum of cardiovascular treatment, predicting the evolution of the disease and the immediate and mid-term outcome of treatment. Operational clustering is going to provide a seamless clinical solution that applies different modeling methods to realize the potential of personalised medicine taking into account user-friendliness as a key component of clinical usability. CARDIOPROOF's goal is to provide first-hand data on comparative cost-effectiveness and clinical efficacy of the most advanced VPH approaches compared to conventional diagnostics and treatment algorithms, thus accelerating the deployment of VPH methods in clinical environments, and bring to maturity holistic patient-specific computer-based predictive models and simulations.